Get started
Author

Michael Jäger

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study
2007 · Alexander Burges, Pauline Wimberger, et al. · Clinical Cancer Research · 257
Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer
2006 · Philipp Kiewe, Stephan Hasmüller, et al. · Clinical Cancer Research · 197
Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)
2011 · Michael Jäger, Alexandra Schoberth, et al. · Cancer Research · 117
PDF
Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
2007 · P Ruf, O Gires, et al. · British Journal of Cancer · 102
PDF
The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
2009 · Michael Jäger, Alexandra Schoberth, et al. · Cancer Research · 94
PDF
Lytic Replication of Epstein-Barr Virus in the Peripheral Blood: Analysis of Viral Gene Expression in B Lymphocytes During Infectious Mononucleosis and in the Normal Carrier State
1997 · Nadja S. Prang, Mathias W. Hornef, et al. · Blood · 90
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
2010 · Peter Ruf, Michael Kluge, et al. · British Journal of Clinical Pharmacology · 88
PDF
Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3)
2009 · Martin Sebastian, Philipp Kiewe, et al. · Journal of Immunotherapy · 65
Epstein-Barr Virus Infection of Human Astrocyte Cell Lines
1999 · Anne Menet, Cornelia Speth, et al. · Journal of Virology · 59
PDF
Two new trifunctional antibodies for the therapy of human malignant melanoma
2003 · Peter Ruf, Michael Jäger, et al. · International Journal of Cancer · 52
Epstein-Barr Virus Small RNA (EBER) Genes: Differential Regulation during Lytic Viral Replication
1998 · Norbert Greifenegger, Michael Jäger, et al. · Journal of Virology · 46
Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
2022 · Eliott Lafon, Michael Jäger, et al. · Journal of Allergy and Clinical Immunology · 26
The control of lytic replication of Epstein-Barr virus in B lymphocytes (Review).
1998 · F Schwarzmann, M Jäger, et al. · International Journal of Molecular Medicine · 24
Epstein-Barr Viral Gene Expression in B-Lymphocytes
1998 · Fritz Schwarzmann, Michael Jäger, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis
1998 · Michael Jäger, Gerlinde Benninger-Döring, et al. · International Journal of Cancer · 15
First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report
2011 · Klaus Pietzner, Michael Jäger, et al. · Medical Oncology · 13
Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen
2022 · Michael Jäger, Stefanie Dichtl, et al. · The Journal of Infectious Diseases · 8
Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation
2023 · Stefanie Dichtl, Gabriel Diem, et al. · Antiviral Research · 7
Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees
2022 · Michael Jäger, Sissy Therese Sonnleitner, et al. · Frontiers in Immunology · 6
Determination of the clean‐up efficiency of the solid‐phase extraction of rosemary extracts: Application of full‐factorial design in hyphenation with Gaussian peak fit function
2017 · Florian Meischl, Christian Günter Kirchler, et al. · Journal of Separation Science · 6
Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
2023 · Michael Jäger, Gabriel Diem, et al. · The Journal of Infectious Diseases · 4
Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites.
2011 · P. Ruf, M. Jäger, et al. · Journal of Clinical Oncology · 4
Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study
2009 · M. Jäger, A. Schoberth, et al. · Journal of Clinical Oncology · 4
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
2023 · Gabriel Diem, Michael Jäger, et al. · Microbiology Spectrum · 3
Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.
2014 · Nicole Haense, Claudia Pauligk, et al. · Journal of Clinical Oncology · 3
Works count: 33
Citation count: 1,306
H-index: 15
I10-index: 16
Year
Topic
Type